Interface Biologics has signed a definitive licence and supply agreement with Navilyst Medical, a leading manufacturer of image-guided medical technologies.
The agreement gives Navilyst exclusive access to Interface Biologics’ Endexo technology.
Go deeper with GlobalData
Endexo is a self-locating bio-medical polymer additive that reduces platelet adhesion, protein adsorption and thrombus formation.
Navilyst Medical chairman and CEO Ron Sparks said that Endexo technology enhances the biocompatibility of the company’s vascular access products.
Navilyst Medical has introduced BioFloPICCs with Endexo Technology, following Canadian approval in August.
See Also:
Interface Biologics is a developer of transformative biomedical polymer technology to improve the safety and effectiveness of medical devices.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
